Skip to content

Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes"

Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes" : single blinded study - Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050340
Enrollment
36
Registered
2023-02-15
Start date
2023-02-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult female

Interventions

test article 1&quot
for 4 weeks Use &quot
test article 2&quot
for 4 weeks Do not use any test articles

Sponsors

Japan Clinical Trial Association
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Subjects whose wrinkle class in the outer corner is 1 to 3 2. Subjects whose skin is dry 3. Subjects with blemishes, pigmentation, or sagging of the face

Exclusion criteria

Exclusion criteria: 1.Pregnant women, those who may be pregnant, and those who are breastfeeding 2.Subjects who work night shifts or day and night shifts 3.Subjects who need help from others and are unable to walk independently 4.Participating in other clinical trials 5.Factors that may affect the test results (disease such as atopic dermatitis and urticaria, inflammation, eczema, trauma, acne, cheeks with a diameter of 5 cm or more) on the test site (both cheeks) Tumor warts, etc., or traces thereof) 6.Subjects who are judged by the investigator to be unsuitable for participation in this study

Design outcomes

Primary

MeasureTime frame
Device evaluation

Secondary

MeasureTime frame
Subjective evaluation

Countries

Japan

Contacts

Public ContactTakeshi Kaneko

Japan Clinical Trial Association N.A.

info@yakujihou.org0364574666

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026